Veracyte

Veracyte is a pioneering global molecular diagnostics and genomic testing company fundamentally dedicated to transforming cancer care through advanced AI and bioinformatics. Founded in 2008 and headquartered in South San Francisco, California, the company operates at the critical intersection of clinical genomics and personalized medicine. Under the hood, Veracyte leverages its proprietary Diagnostics Platform to analyze transcriptomes, genomes, and real-world clinical data, delivering highly accurate risk-assessment tests like Afirma (thyroid), Decipher (prostate and bladder), and Prosigna (breast). Their primary target audience spans oncologists, urologists, endocrinologists, and healthcare networks who need to replace diagnostic ambiguity with precision data—enabling personalized treatment plans and preventing unnecessary, invasive surgeries. What sets Veracyte apart in the competitive biotechnology landscape is its staggering evidence-generation engine and proven clinical utility; having guided care decisions for over 800,000 patients and securing inclusion in major NCCN guidelines, completely transforming how complex tumor biology is mapped and treated worldwide.